Symbio Generrics India Profile
Key Indicators
- Authorised Capital ₹ 3.10 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.01 Cr
as on 16-11-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 235.81 Cr
as on 16-11-2024
- Satisfied Charges ₹ 17.51 Cr
as on 16-11-2024
- Revenue 7.64%
(FY 2023)
- Profit -52.56%
(FY 2023)
- Ebitda -49.36%
(FY 2023)
- Net Worth 62.24%
(FY 2023)
- Total Assets 70.45%
(FY 2023)
About Symbio Generrics India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.10 Cr and a paid-up capital of Rs 3.01 Cr.
The company currently has active open charges totaling ₹235.81 Cr. The company has closed loans amounting to ₹17.51 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Symbio Generrics India Private Limited India is Akash Puranik as CEO. Ajay Mittal, Kannan Sharma, Akash Puranik, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74990KA2011PTC184231
- Company No.
080853
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Symbio Generrics India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akash Puranik  | Managing Director | 30-Sep-2017 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kannan Sharma | Director | 19-Sep-2022 | Current |
| Ajay Mittal | Nominee Director | 30-Mar-2022 | Current |
| Salim Shaikh | Whole-Time Director | 30-May-2011 | Current |
| Deepak Komaregowda | Nominee Director | 30-Mar-2022 | Current |
Financial Performance and Corporate Structure Insights of Symbio Generrics India.
Symbio Generrics India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.64% increase. The company also saw a substantial fall in profitability, with a 52.56% decrease in profit. The company's net worth Soared by an impressive increase of 62.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbio Generrics India?
In 2023, Symbio Generrics India had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbio Natural Products Private LimitedActive 7 years 1 monthAkash Puranik and Salim Shaikh are mutual person
I-Nurture Education Solutions Private LimitedActive 20 years 5 monthsDeepak Komaregowda is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jun 2024 | ₹12.00 Cr | Open |
Citi Bank N.A. Creation Date: 14 Dec 2023 | ₹25.00 Cr | Open |
Axis Bank Limited Creation Date: 11 Dec 2023 | ₹30.00 Cr | Open |
How Many Employees Work at Symbio Generrics India?
Symbio Generrics India has a workforce of 161 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbio Generrics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbio Generrics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
